|
|
|
| LINK CHINA PHARMA SOLUTIONS BROKERED STRATEGIC PARTNERSHIP DEAL BETWEEN DUTCH-MUCOSIS BV AND BCHT BIOTECH OF CHINA ADVANCES WELL |
|
21 May 2015
UK Cambridge based Link China Pharma Solutions successfully brokered an equity investment and long-term collaboration license agreement between Dutch Groningen based Biotechnology company Mucosis B.V. and China Changchun based BCHT Biotechnology Co (BCHT)last April, after just one year the partnership goes smoothly and the RSV vaccine co-development project is progressing well.
Under the agreement with BCHT, Mucosis has received the full amount of equity investment (around $5m) early this year. The deal also comes along with future customary payments including royalties in return for a license to its SynGEM vaccine candidate for RSV and Mimopath platform for other disease targets within P.R. China on an exclusive basis and non-exclusively in certain other Asian countries. Further details of the agreement were not disclosed..
Changchun BCHT Biotechnology Co., established in 2004 and is a biopharmaceutical enterprise engaging in research, development, production and marketing of vaccines, biologics and peptide drugs. BCHT has well-established innovative platform by the most talented researchers and with the state-of-the-art facility. The management team consists of the members with strong international background and extensive experience in China in biopharmaceutical industry.
"We are pleased with BCHT joining a group of investors who already at an early stage shared our confidence in the potential of our Mimopath® technology and SynGEM® RSV vaccine candidate. We believe that our Mimopath® platform combined with BCHT's expertise in vaccine development creates a substantial opportunity in China and other parts of Asia to develop differentiated and medically relevant vaccines ", said Thomas Johnston, CEO of Mucosis. "We see this partnership as a further validation of our clinical-stage platform and its potential to combat infectious diseases. Lastly, we are grateful to Link China Pharma Solutions of Cambridge, UK for their invaluable assistance in brokering this deal."
“We are delighted to form this solid partnership with Mucosis BV to advance RSV vaccine program and develop other vaccine candidates based on Mimopath® platform technology, I believe this business relationship between our two companies will strengthen our pipeline of new vaccine products research and development, I sincerely hope the signing of this strategic partnership agreement will bear fruit eventually” said Dr Kong, President of Changchun BCHT Biotechnology Co.
“The Mucosis and BCHT partnership negotiations started just six months ago with our first visit to BCHT back in June, within this short period of time both sides really get down to work very hard with high efficiency and finally agreed this win-win partnership deal. With Mucosis patented RSV vaccine program and unique proprietary Memopath technology platform, and also with the support from BCHT parent company, the highly competent BCHT management team and successful biological products development experience, one thing can be sure that this China-Dutch technology company partnership will make good progress in years to come and I am extremely proud of the signing of this partnership deal”, said Marshall Ma, MD of Link China Pharma Solutions.
In addition to BCHT, the Series C financing round was supported by Mucosis’s current investors, which include BioGeneration Ventures, MedSciences Seed Fund, MedSciences Capital, NV NOM (Investment and Development Agency for the Northern Netherlands), and Utrecht University Holding/UMC Utrecht Holding.
SynGEM® , Mucosis’s lead vaccine candidate, is developed in cooperation with corporate, governmental and non-governmental partners across the globe. SynGEM® is designed to prevent infections with Respiratory Syncytial Virus (RSV), which affect over 60 million people worldwide ranging from the very young to the elderly with more than one million hospitalizations annually. An RSV vaccine does not yet exist.
About Mucosis
Mucosis B.V. is a clinical-stage Dutch biotechnology company with a proprietary platform technology, Mimopath®, on which it develops mucosal vaccines with improved efficacy. Mucosis’s lead product is SynGEM®, a vaccine to prevent RSV infection. In addition, the company develops PneuGEM®, a vaccine to prevent diseases caused by pneumococcal bacteria and FluGEM®, a vaccine to prevent influenza. Mimopath®-based vaccines can be administered needle-free in the nose and mouth, evoking a more natural immune response with a broader base of protection.
About Mimopath® technology
The Mimopath® technology is based on Lactococcus lactis, a Generally Recognized As Safe (GRAS) bacterium commonly used in the food industry. Mucosis has developed a robust technique to formulate the L. lactis bacteria into non-living bacterium-like particles (BLPs) that can be loaded with antigens from viral, bacterial, parasitic or tumor origin. The antigen-covered BLPs form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These vaccines have been shown to raise protective immunity by activation of both the innate and the adaptive immune system.
About Link China Pharma Solutions
Link China Pharma Solutions (“LCPS”) is a UK Cambridge based dedicated technology brokerage and services provider bringing in-depth China industry experience and market knowledge to provide a range of specialist services to promote research co-operation, technology transfer and business collaboration between China and UK/EU life science research institutes, biotech and pharmaceutical companies to maximize the value of research and business alliances. LCPS is specialized in supporting UK/EU small, medium and large biopharmaceutical and life science companies to build the collaboration with Chinese partners and provide a full suite of services from strategy alignment, partnership selection, collaborative partnering, outsourcing transaction in drug discovery and development, clinical trial, contract manufacturing, to China market entry and development so that our clients can minimize the cost, gain the competitive advantage in the global market and place themselves well ahead to access one of the fastest growing pharmaceutical markets in the world.
” |
|
